KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EBIT (2016 - 2025)

Historic EBIT for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to -$38.9 million.

  • Pacific Biosciences Of California's EBIT rose 3932.77% to -$38.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$665.7 million, marking a year-over-year decrease of 6282.74%. This contributed to the annual value of -$474.3 million for FY2024, which is 4181.16% down from last year.
  • Pacific Biosciences Of California's EBIT amounted to -$38.9 million in Q3 2025, which was up 3932.77% from -$44.9 million recorded in Q2 2025.
  • Pacific Biosciences Of California's 5-year EBIT high stood at -$33.7 million for Q1 2021, and its period low was -$428.9 million during Q1 2025.
  • Moreover, its 5-year median value for EBIT was -$74.6 million (2022), whereas its average is -$96.8 million.
  • The largest annual percentage gain for Pacific Biosciences Of California's EBIT in the last 5 years was 7449.3% (2025), contrasted with its biggest fall of 42719.21% (2025).
  • Over the past 5 years, Pacific Biosciences Of California's EBIT (Quarter) stood at -$64.7 million in 2021, then tumbled by 34.65% to -$87.1 million in 2022, then dropped by 0.53% to -$87.5 million in 2023, then tumbled by 74.79% to -$153.0 million in 2024, then surged by 74.59% to -$38.9 million in 2025.
  • Its EBIT was -$38.9 million in Q3 2025, compared to -$44.9 million in Q2 2025 and -$428.9 million in Q1 2025.